Valuation: Norda ASA

Market Cap 513M 51.81M 45.35M 41.86M 39.05M 73.57M 4.9B 74.88M 502M 195M 2.42B 195M 190M 8.42B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 26.69M 23.36M 21.56M 20.11M 37.9M 2.52B 38.58M 259M 100M 1.25B 100M 98.02M 4.34B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
3 months+1.53%
6 months-13.60%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 80.1
Extreme 80.1
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 07/04/2013
Director TitleAgeSince
Chairman 54 30/01/2014
Director/Board Member 68 19/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+8.00%+110.73% 44.67M
+1.15%+5.94%-3.40%+2.32% 46.62B
-2.35%+11.02%+411.54%+603.53% 40.95B
+0.19%+12.61%+22.39%-14.19% 32.26B
-1.45%+3.42%+17.97%+60.16% 32.24B
-3.29%+2.85%+13.80%+30.30% 25.53B
+1.88%+11.91% - - 16.38B
+0.52%+13.16%+70.72%+123.10% 15.27B
+0.56%+5.09%+13.43%+17.88% 13.61B
-0.63%+5.92%+103.72%+96.17% 13.34B
Average -0.17%+9.45%+73.13%+114.45% 23.62B
Weighted average by Cap. -0.51%+10.36%+95.49%+138.68%

Financials

2023 2024
Net sales 86.92M 8.77M 7.68M 7.09M 6.61M 12.46M 830M 12.68M 85.05M 33.02M 409M 32.97M 32.23M 1.43B 372M 37.54M 32.86M 30.33M 28.29M 53.31M 3.55B 54.26M 364M 141M 1.75B 141M 138M 6.1B
Net income 31.17M 3.15M 2.75M 2.54M 2.37M 4.47M 298M 4.55M 30.5M 11.84M 147M 11.82M 11.56M 512M 126M 12.71M 11.13M 10.27M 9.58M 18.06M 1.2B 18.38M 123M 47.84M 593M 47.77M 46.7M 2.07B
Net Debt -311M -31.42M -27.5M -25.39M -23.68M -44.62M -2.97B -45.42M -305M -118M -1.47B -118M -115M -5.11B -249M -25.12M -21.99M -20.3M -18.93M -35.67M -2.38B -36.31M -243M -94.51M -1.17B -94.37M -92.26M -4.08B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock